B-cell-targeted therapy in adult glomerulonephritis (Q38159787)

30 August 2017

title

B-cell-targeted therapy in adult glomerulonephritis (English)

1 reference

30 August 2017

1 reference

Anisha Tanna

1

1 reference

30 August 2017

Frederick W K Tam

series ordinal

2

1 reference

30 August 2017

Charles D Pusey

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

5 November 2013

1 reference

Expert Opinion on Biological Therapy

30 August 2017

published in

1 reference

30 August 2017

volume

13

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

1691-1706

1 reference

Treatment of nephrosis with cortisone

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Regulation of immunity and autoimmunity by B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Drug insight: rituximab in renal disease and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Update on the role of rituximab in kidney diseases and transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

BAFF AND APRIL: a tutorial on B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Targeting BAFF in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The immunological basis of B-cell therapy in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Management of membranous nephropathy: when and what for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab treatment of idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The treatment of minimal change disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Pathogenesis of lipoid nephrosis: a disorder of T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Permeability factors in focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab therapy in nephrotic syndrome: implications for patients' management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab in children with resistant idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Severe Henoch-Schönlein purpura induced by cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Refractory Henoch-Schönlein purpura: atypical aetiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Regulatory B cells in ANCA-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

B-cell depletion in the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Lupus nephritis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Biologic and clinical significance of cryoglobulins. A report of 86 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The clinical and morphologic spectrum of renal cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab therapy for membranous nephropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

Clinical and histopathologic findings in adults with the nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.851191

10.1517/14712598.2013.851191

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference